Tudriqev is an engineered herpes-virus therapy approved with nivolumab for certain advanced melanoma after anti-PD-1 treatment. Here is what the 24.2% response rate and accelerated approval do—and do not—show.
The FDA granted accelerated approval on August 6, 2026 to Tudriqev (vusolimogene oderparepvec, also called RP1) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed after an anti-PD-1-based regimen.
Tudriqev is an engineered herpes simplex virus designed to infect and destroy tumor cells while helping stimulate an anti-tumor immune response. It is administered into tumors by trained oncology professionals; it is not related to consumer herpes treatments and cannot be used outside a cancer-care setting.
In the study supporting the approval, the combination produced an objective response rate of 24.2% in this difficult-to-treat population. Response rate describes the proportion of patients whose tumors shrink by a specified amount; it is not the same as cure rate, overall survival, or a guarantee for an individual patient.
Accelerated approval is an FDA pathway for serious conditions with unmet need. It may rely on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict benefit. In this case, continued approval is contingent on a confirmatory study verifying clinical benefit.
That caveat should be prominent in any discussion of the news. Tudriqev is an important option for a defined group of patients after progression on anti-PD-1 therapy, but the evidence base is still developing.
Sunscreen cannot treat melanoma or substitute for dermatology care. Consistent broad-spectrum sun protection is one evidence-informed way to reduce future UV exposure. We may earn a commission from the following link at no extra cost to you.
Tudriqev plus nivolumab is a meaningful new option for a narrowly defined advanced-melanoma setting, with a 24.2% response rate in the supporting study. The accelerated-approval status means ongoing confirmatory evidence matters. Any treatment decision belongs with a medical oncology team.